CORRESP Filing
Kymera Therapeutics, Inc.
Date: April 30, 2025 · CIK: 0001815442 · Accession: 0001193125-25-107469
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-39460
Referenced dates: April 25, 2025
Letter
Re: Kymera Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2024 File No. 001-39460 Ladies and Gentlemen, Kymera Therapeutics, Inc. (the “Company,” “we,” “us” or “our”) is submitting this letter in response to comments of the staff of the Division of Corporation Finance (the “Staff”) of the Securities and Exchange Commission (the “Commission”), received by letter dated April 25, 2025 (the “Comment Letter”), relating to the Company’s Form 10-K for the fiscal year ended December 31, 2024 filed with the Commission on February 27, 2025 (the “Form 10-K”). For your convenience, the Staff’s comment is reproduced in bold type below, followed by the Company’s response thereto. Form 10-K for Fiscal Year Ended December 31, 2024 Note 13 - Net Loss per Share, page F-32
VIA EDGAR April 30, 2025 Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3628 Attention: Tara Harkins, Gary Newberry
1. We note the 15.2 million pre-funded warrants outstanding disclosed in Note 1 and the risk of potential dilution described on page 76. Please revise future filings to provide the following:
•
Reconcile the denominator used for basic per share computations to show the effect of all securities that impact earnings per share. Refer to ASC 260-10-50-1 and 260-10-55-53.
•
Describe any reasonably likely material changes in the mix of your capital resources necessary to understand your financial condition due to the dilution of the warrants within your MD&A in Item 7. Refer to Item 303(b)(1)(ii)(B) of Regulation S-K. Response : In response to the Staff’s comment, in future filings beginning with the Company’s Form 10-Q for the fiscal quarter ended March 31, 2025, as appropriate, the Company will reconcile the denominator used for basic per share computations to show the effect of all securities that impact earnings per share and describe any reasonably likely material changes in the mix of the Company’s capital resources necessary to understand the Company’s financial condition due to the dilution of the warrants within the Company’s Management’s Discussion and Analysis of Financial Condition and Results of Operations.
April 30, 2025 Page 2 If you or any other member of the Staff have any questions regarding the foregoing responses, would like to discuss any of the matters covered in this letter, or otherwise require additional information, please do not hesitate to contact the undersigned at (857) 285-5314.
Sincerely,
/s/ Bruce Jacobs
Show Raw Text
CORRESP 1 filename1.htm CORRESP VIA EDGAR April 30, 2025 Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3628 Attention: Tara Harkins, Gary Newberry Re: Kymera Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2024 File No. 001-39460 Ladies and Gentlemen, Kymera Therapeutics, Inc. (the “Company,” “we,” “us” or “our”) is submitting this letter in response to comments of the staff of the Division of Corporation Finance (the “Staff”) of the Securities and Exchange Commission (the “Commission”), received by letter dated April 25, 2025 (the “Comment Letter”), relating to the Company’s Form 10-K for the fiscal year ended December 31, 2024 filed with the Commission on February 27, 2025 (the “Form 10-K”). For your convenience, the Staff’s comment is reproduced in bold type below, followed by the Company’s response thereto. Form 10-K for Fiscal Year Ended December 31, 2024 Note 13 - Net Loss per Share, page F-32 1. We note the 15.2 million pre-funded warrants outstanding disclosed in Note 1 and the risk of potential dilution described on page 76. Please revise future filings to provide the following: • Reconcile the denominator used for basic per share computations to show the effect of all securities that impact earnings per share. Refer to ASC 260-10-50-1 and 260-10-55-53. • Describe any reasonably likely material changes in the mix of your capital resources necessary to understand your financial condition due to the dilution of the warrants within your MD&A in Item 7. Refer to Item 303(b)(1)(ii)(B) of Regulation S-K. Response : In response to the Staff’s comment, in future filings beginning with the Company’s Form 10-Q for the fiscal quarter ended March 31, 2025, as appropriate, the Company will reconcile the denominator used for basic per share computations to show the effect of all securities that impact earnings per share and describe any reasonably likely material changes in the mix of the Company’s capital resources necessary to understand the Company’s financial condition due to the dilution of the warrants within the Company’s Management’s Discussion and Analysis of Financial Condition and Results of Operations. April 30, 2025 Page 2 If you or any other member of the Staff have any questions regarding the foregoing responses, would like to discuss any of the matters covered in this letter, or otherwise require additional information, please do not hesitate to contact the undersigned at (857) 285-5314. Sincerely, /s/ Bruce Jacobs Bruce Jacobs Chief Financial Officer